FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2026/02/104537 [Registered on: 23/02/2026] Trial Registered Prospectively
Last Modified On: 22/02/2026
Post Graduate Thesis  Yes 
Type of Trial  Observational 
Type of Study   Retrospective Study 
Study Design  Other 
Public Title of Study   A Study of Treatment Methods and Survival Outcomes in Patients with Glioma (Brain Tumor) Treated with Curative Therapy 
Scientific Title of Study   Glioma outcomes and benchmark evaluation at HBCHRC, Vizag-GLOBE 
Trial Acronym  NILL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Umesh Mahantshetty 
Designation  Professor 
Affiliation  Homi Bhabha Cancer Hospital and Research Centre 
Address  Room No. 104, Department of Radiation Oncology, Radiation block, Homi Bhabha Cancer Hospital and Research Centre, Aganampudi, Gajuwaka Mandalam, Visakhapatnam ANDHRA PRADESH 530053 India

Visakhapatnam
ANDHRA PRADESH
533053
India 
Phone  9819885774  
Fax    
Email  drumeshm@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Samyak Jain 
Designation  PG Resident 
Affiliation  Homi Bhabha Cancer Hospital and Research Centre 
Address  Room No. 105, Department of Radiation Oncology, Radiation block, Homi Bhabha Cancer Hospital and Research Centre, Aganampudi, Gajuwaka Mandalam, Visakhapatnam ANDHRA PRADESH 530053 India

Visakhapatnam
ANDHRA PRADESH
533053
India 
Phone  8899982286  
Fax    
Email  samragnarokjain@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Umesh Mahantshetty 
Designation  Professor 
Affiliation  Homi Bhabha Cancer Hospital and Research Centre 
Address  Room No. 104, Department of Radiation Oncology, Radiation block, Homi Bhabha Cancer Hospital and Research Centre, Aganampudi, Gajuwaka Mandalam, Visakhapatnam ANDHRA PRADESH 530053 India

Visakhapatnam
ANDHRA PRADESH
533053
India 
Phone  9819885774  
Fax    
Email  drumeshm@gmail.com  
 
Source of Monetary or Material Support  
Homi Bhabha Cancer Hospital and Research Centre, Tata Memorial Centre, Aganampudi, Gajuwaka Mandalam, Visakhapatnam, Andhra Pradesh, 533053, India 
 
Primary Sponsor  
Name  Homi Bhabha Cancer Hospital and Research Centre, Tata Memorial Centre 
Address  Aganampudi, Gajuwaka Mandalam, Visakhapatnam (Andhra Pradesh)- 530053 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Samyak Jain  Homi Bhabha Cancer Hospital and Research Centre  Room No. 104, Department of Radiation Oncology, Radiation block, Homi Bhabha Cancer Hospital and Research Centre, Aganampudi, Gajuwaka Mandalam, Visakhapatnam ANDHRA PRADESH 530053 India
Visakhapatnam
ANDHRA PRADESH 
8899982286

samragnarokjain@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
HBCH RC Ethics Committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: C719||Malignant neoplasm of brain, unspecified,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Nil  Nil 
 
Inclusion Criteria  
Age From  0.00 Year(s)
Age To  99.00 Year(s)
Gender  Both 
Details  Glioma cases who received at least one of the adjuvant treatment in HBCHRC, Vizag. 
 
ExclusionCriteria 
Details  Patients who received EBRT outside HBCHRC

Patient with recurrent/progressive disease at presentation
 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
To evaluate patterns of care in patients with glioma treated at HBCHRC, Vizag over January 1st , 2020 till December 31st , 2024  2 Years 
 
Secondary Outcome  
Outcome  TimePoints 
1. To assess compliance to planned treatment protocols.

2. To assess documentation, completeness of diagnostic and staging workup, including MRI, histopathology and molecular markers

3. To evaluate treatment related toxicities and unplanned treatment interruptions

4. To assess follow-up patterns and imaging surveillance post treatment

5. To identify prognostic factors influencing PFS (Progression Free Survival) and OS (Overall Survival)

6. To identify gaps in care delivery and areas of quality improvement

7. To propose recommendations/ action plans

8. To assess follow-up patterns and imaging surveillance post treatment

9. To assess response to treatment as per RANO criteria
 
2 Years 
 
Target Sample Size   Total Sample Size="150"
Sample Size from India="150" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   22/03/2026 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  22/03/2026 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="2"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  
Gliomas constitute the most common primary malignant brain tumors and require multidisciplinary management involving surgery, radiotherapy, and chemotherapy. While international guidelines emphasize molecular classification and quality indicators of care, real-world data on patterns of care, treatment compliance, and outcomes from Indian centers remain limited.

This retrospective observational study aims to evaluate patterns of care, quality indicators, treatment compliance, toxicities, and clinical outcomes in patients with glioma treated at Homi Bhabha Cancer Hospital and Research Centre (HBCHRC), Visakhapatnam, between January 2020 and December 2024. The study will benchmark institutional practices against guideline-based standards and identify gaps in care delivery.

Data will be collected from electronic medical records, radiology (PACS), and radiation oncology information systems (ROIS), including demographic details, diagnostic workup, surgical and pathological findings, molecular testing, treatment details, toxicities, follow-up patterns, and disease outcomes. Survival outcomes such as progression-free survival (PFS) and overall survival (OS) will be analyzed, and response assessment will be performed using RANO criteria.

The findings are expected to provide real-world evidence on glioma management, help identify areas for quality improvement, and guide future institutional protocols and research initiatives.

 
Close